CTOs on the Move


 
Unlike traditional approaches that only address symptoms, Cardionomic addresses the conditions root cause of reduced contractility. The therapy uses neuromodulation to benignly increase contractility, thus improving cardiac output therefore increasing renal flow and end organ perfusion. Benignly increasing contractility decreases negative hormonal signaling, and improves in-hospital morbidity/mortality. This breakthrough therapy is also expected to increase pharmacological tolerance at discharge, which will reduce costly readmission and extend life. Spun off from Denali Medical II, a New Enterprise Associates (NEA) backed incubator, Cardionomic is funded by NEA, Greatbatch Medical and Cleveland Clinic Foundation.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.cardionomicinc.com
  • 2009 West Broadway Ave Ste 400, PMB 130
    Forest Lake, MN USA 55025
  • Phone: 651.964.0170

Executives

Name Title Contact Details

Funding

Cardionomic raised $20M on 10/26/2015

Similar Companies

Athena Diagnostics, Inc.

Athena Diagnostics, Inc. is a commercial diagnostic laboratory focused on performing esoteric tests, which the Company refers to as assays, primarily in the field of neurology.

Acumen Research Group

Acumen Research Group Inc. is a London, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Flyana.Com Inc

Flyana.Com Inc is a Anahola, HI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MedAxiom

MedAxiom is a Neptune Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BTG International

BTG is a global healthcare company focused on Interventional Medicine. Our innovative medical technology helps physicians treat their patients through minimally invasive procedures. Today we have a growing portfolio of products that advance the treatment of cancer, vascular conditions and severe emphysema. Our Pharmaceuticals business provides products that help patients overexposed to certain medications or toxins. Our mission is to provide imaginative new ways to treat disease; making a real difference for patients, and a valuable contribution to healthcare. As medicine moves from major surgery to minor procedure, no company endeavours to do more to help doctors in their quest to see more, reach further and treat smarter. We understand their needs and equip them with tools and techniques that would have seemed like science fiction only a generation ago. We invest in clinical evidence that helps demonstrate the value of our treatments to patients, doctors, and healthcare systems. With relentless curiosity we`ll work with clinicians to find elegant new ways to extend our power over disease and transform patient care. There are no limits to where our ideas will take us.